Latest news with #autoimmune
Screen Geek
12 hours ago
- Entertainment
- Screen Geek
'The Boys' Star Erin Moriarty Shares Graves' Disease Diagnosis
The Boys star Erin Moriarty has shared some serious news on social media. According to Erin Moriarty, who plays the fan-favorite character Starlight in the hit Amazon Prime series The Boys , she has been officially diagnosed with Graves' disease. Moriarty made the announcement via Instagram, where she also took the opportunity to share some words of inspiration for others that might be dealing with similar health issues. 'Autoimmune disease manifests differently in everybody/every body,' she opens her statement with. 'Your experience will be different from mine. My experience will be different from yours. Perhaps greatly, perhaps minutely,' she adds. 'One thing I can say: if I hadn't chalked it all up to stress and fatigue, I would've caught this sooner.' At this point, Erin Moriarty explains the situation with his Graves' disease diagnosis: 'A month ago, I was diagnosed with Graves' disease. Within 24 hours of beginning treatment, I felt the light coming back on. It's been increasing in strength ever since. If yours is dimming, even slightly, go get checked. Don't 'suck it up' and transcend suffering; you deserve to be comfy. Shit's hard enough as is.' Graves' disease is an immune system condition that specifically effects the thyroid gland. As shared via Mayo Clinic, it 'causes the body to make too much thyroid hormone.' Although these diagnoses are certainly unfortunate news for anyone that receives them, it's nice seeing Moriarty is already feeling better and receiving the care that she needs to battle the disease. Likewise, it's nice to see her share words of wisdom for anyone dealing with similar situations. It absolutely is hard enough without the opportunity to feel comfortable with your personal health. Stay tuned to ScreenGeek for any additional updates regarding Erin Moriarty and the Amazon Prime series The Boys as we have them. The Boys will return for a fifth and final season that has yet to receive an official release date, with several spin-off projects also in the works.
CTV News
3 days ago
- Health
- CTV News
Marking Scleroderma Awareness Month
Atlantic Watch A woman recently diagnosed with scleroderma shares what she wishes people would know about the autoimmune disease.
Globe and Mail
4 days ago
- Health
- Globe and Mail
Dermatomyositis Market Set to Advance with Improved Diagnosis and Emerging Immunotherapies by 2034
Dermatomyositis is a rare, chronic, inflammatory myopathy characterized by progressive muscle weakness and distinctive skin rashes, often associated with autoimmune mechanisms. It can occur in both adults and children and may involve complications such as interstitial lung disease, malignancy, and calcinosis. Despite its rarity, dermatomyositis remains a significant clinical concern due to its multisystem involvement, diagnostic complexity, and limited treatment options. DelveInsight's ' Dermatomyositis Market Insight, Epidemiology, and Market Forecast – 2034 ' provides an in-depth analysis of the current landscape and future outlook of the DM market across major geographies, including the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The report explores detailed epidemiological trends, segmentation by age and clinical subtypes, and diagnostic challenges that contribute to underreporting and delayed intervention. Current treatment regimens typically include corticosteroids, immunosuppressants (methotrexate, azathioprine), intravenous immunoglobulin (IVIG), and emerging biologics like rituximab. However, response rates vary, and long-term use can lead to significant side effects. A growing pipeline of investigational agents—targeting pathways such as type I interferons and B-cell modulation—offers promising avenues for disease-specific and steroid-sparing therapies. The Dermatomyositis market is projected to witness steady growth through 2034, fueled by increased disease recognition, clinical trial activity, and strategic advancements by pharmaceutical companies. Biotech firms and academic institutions are exploring novel immunomodulatory agents and precision medicine approaches to improve outcomes in both adult and pediatric populations. DelveInsight's report is an essential resource for pharmaceutical executives, clinical researchers, investors, and healthcare professionals who seek strategic insights into the evolving DM landscape, from market dynamics and unmet needs to the competitive pipeline shaping the future of dermatomyositis care. Some of the Key Facts of the Dermatomyositis Market Report: • In 2023, the dermatomyositis market in the 7MM was valued at approximately USD 187 million, and is projected to grow at a CAGR of 16.8% due to improved disease awareness, diagnostics, and the introduction of new therapies. • The U.S. had the highest number of diagnosed cases, with around 38.5K in 2023. • Across the 7MM, there were nearly 72K diagnosed prevalent cases in 2023, with 91% in adults and 9% in juveniles. • The U.S. accounted for ~54% of total diagnosed cases, while EU4 and the UK represented about 29%, and Japan ~17%. • In January 2025, RESTEM announced that the FDA granted Fast Track designation for its Restem-L program, using umbilical cord outer lining stem cells (ULSCs) to treat Polymyositis and Dermatomyositis (PM/DM), now classified as Idiopathic Inflammatory Myopathy (IIM). This follows the recent Orphan Drug Designation for Restem-L in IIM. • In July 2024, Priovant Therapeutics announced the completion of enrollment for its Phase 3 VALOR trial evaluating brepocitinib in dermatomyositis. With 241 participants across 90 sites on four continents, it is the largest interventional trial ever conducted for the condition. • Leading companies in the Dermatomyositis market include Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals, and others. • Emerging acute Dermatomyositis drugs include KZR-616, EFG PH20, PF 06823859, Hizentra, Daxdilimab, PN 101, Ravulizumab, and others. • The increasing prevalence of dermatomyositis and ongoing advancements in therapeutic options are driving the demand for more effective treatment approaches. To know in detail about the dermatomyositis market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Dermatomyositis Market Forecast Dermatomyositis Overview Dermatomyositis is a rare, systemic autoimmune disorder characterized by chronic inflammation of the skin and muscles. It presents with hallmark features such as symmetric proximal muscle weakness and distinctive skin rashes, including the heliotrope rash and Gottron's papules. The condition may also affect other organs, including the lungs, esophagus, and heart, and is sometimes associated with malignancy, especially in adults. Dermatomyositis affects both adults and children (juvenile dermatomyositis), with varying severity. Its exact etiology remains unclear but is believed to involve a combination of genetic predisposition, immune system dysregulation, and environmental triggers. Diagnosis typically involves a combination of clinical findings, elevated muscle enzymes, electromyography (EMG), imaging studies, skin/muscle biopsies, and autoantibody testing. Management of dermatomyositis requires a multidisciplinary approach, involving dermatologists, rheumatologists, neurologists, and physical therapists. While there is no cure, a range of therapies aim to control inflammation, alleviate symptoms, and prevent complications. Get a free sample of the dermatomyositis market report with key insights and emerging therapies here: Dermatomyositis Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Dermatomyositis Epidemiology Segmentation: The Dermatomyositis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by: • Diagnosed Dermatomyositis prevalence • Type-specific Diagnosed Dermatomyositis prevalence • Age-specific Diagnosed Dermatomyositis prevalence • Gender-specific Diagnosed Prevalent Cases of Dermatomyositis • Severity-specific Diagnosed Prevalent Cases of Dermatomyositis • Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis Download the report to understand which factors are driving dermatomyositis epidemiology trends @ Dermatomyositis Epidemiology Forecast Dermatomyositis Drugs Uptake and Pipeline Development Activities The Dermatomyositis drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the Dermatomyositis market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug. Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share. The report further delves into the Dermatomyositis pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies. Dermatomyositis Market Outlook While there is no definitive cure for dermatomyositis, available treatments aim to reduce inflammation, control symptoms, and improve quality of life. The approval of OCTAGAM and the development of multiple clinical management guidelines—such as those from the British Society for Rheumatology and the Japanese Society of Rheumatology—have significantly shaped and standardized the therapeutic landscape. Treatment often begins with corticosteroids to manage muscle inflammation, followed by immunosuppressants or immunomodulators like methotrexate, azathioprine, or mycophenolate mofetil to reduce steroid dependency. For resistant or severe cases, advanced therapies such as rituximab, IVIG, and calcineurin inhibitors are employed. In terms of skin manifestations, management includes both topical agents (e.g., corticosteroids, calcineurin inhibitors) and systemic medications like hydroxychloroquine. Adjunctive strategies such as physiotherapy, sun protection, and dietary interventions are also integral. A growing pipeline featuring therapies like Brepocitinib (Priovant/Pfizer), Dazukibart (Pfizer), Efgartigimod (Argenx), and SAPHNELO (AstraZeneca) reflects an evolving research focus on immunomodulation and interferon signaling pathways. These emerging agents, combined with better diagnostics and increasing disease awareness, are expected to drive market growth through 2034. Dermatomyositis Market Strengths • A strong research focus on immune pathways (e.g., JAK-STAT, interferon) has led to promising investigational drugs such as Brepocitinib and Anifrolumab, indicating future therapeutic breakthroughs. • Increasing awareness among clinicians and availability of diagnostic tools (e.g., autoantibody profiling, MRI) enable earlier diagnosis and more tailored treatment strategies. Dermatomyositis Market Weaknesses • Despite multiple treatment options, none offer a cure, and many patients experience relapses or partial responses, necessitating lifelong management. • A significant portion of treatment regimens relies on off-label drug use, which lacks robust clinical trial data, leading to variable efficacy and safety outcomes across patient populations. Scope of the Dermatomyositis Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] • Key Dermatomyositis Companies: Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals, and others. • Key Dermatomyositis Therapies: KZR-616, EFG PH20, PF 06823859, Hizentra, Daxdilimab, PN 101, Ravulizumab, and others. • Dermatomyositis Therapeutic Assessment: Dermatomyositis, currently marketed, and Dermatomyositis emerging therapies • Dermatomyositis Market Dynamics: Dermatomyositis market drivers and Dermatomyositis market barriers • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies • Dermatomyositis Unmet Needs, KOL's views, Analyst's views, Dermatomyositis Market Access and Reimbursement To learn more about the key players and advancements in the dermatomyositis treatment landscape, visit the Dermatomyositis Market Analysis Report Table of Contents 1. Dermatomyositis Market Report Introduction 2. Executive Summary for Dermatomyositis 3. SWOT analysis of Dermatomyositis 4. Dermatomyositis Patient Share (%) Overview at a Glance 5. Dermatomyositis Market Overview at a Glance 6. Dermatomyositis Disease Background and Overview 7. Dermatomyositis Epidemiology and Patient Population 8. Country-Specific Patient Population of Dermatomyositis 9. Dermatomyositis Current Treatment and Medical Practices 10. Dermatomyositis Unmet Needs 11. Dermatomyositis Emerging Therapies 12. Dermatomyositis Market Outlook 13. Country-Wise Dermatomyositis Market Analysis (2020–2034) 14. Dermatomyositis Market Access and Reimbursement of Therapies 15. Dermatomyositis Market Drivers 16. Dermatomyositis Market Barriers 17. Dermatomyositis Appendix 18. Dermatomyositis Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Associated Press
4 days ago
- Health
- Associated Press
Dr. Ashley Capps Unveils Premium Autoimmune Rebalance System: A Groundbreaking Approach to Autoimmune Recovery Through Trauma-Informed Healing
Dr. Ashley Capps announces the launch of her Autoimmune Rebalance System, offering a premium, trauma-informed healing approach for women to address autoimmune symptoms at their root causes. United States, June 16, 2025 -- Dr. Ashley Capps Introduces a Revolutionary Autoimmune Recovery System Focused on Trauma and Stress In an unconventional move that is redefining autoimmune disease recovery, Dr. Ashley Capps, a behavioral health doctor and licensed mental health therapist, has launched the Autoimmune Rebalance System. This premium, trauma-informed program is designed specifically to help women tackle the root causes of autoimmune diseases by focusing on the often-overlooked contributors of chronic stress, unresolved trauma, and nervous system dysregulation. Dr. Capps' approach challenges the traditional medical model, which often isolates the physical and mental aspects of health. By incorporating modern psychoneuroimmunology research, Dr. Capps provides a comprehensive, holistic framework for autoimmune recovery. This innovative program emphasizes the mind-body connection as a central pillar of healing, offering a more sustainable and integrated solution for those suffering from autoimmune conditions. The Trauma-Informed Approach to Autoimmune Recovery Unlike conventional programs that primarily focus on symptom management through diet, medications, or supplements, Dr. Capps' Autoimmune Rebalance System integrates trauma recovery at its core. By addressing the mental, emotional, and neurological influences on immune system function, Dr. Capps offers a comprehensive healing process that goes far beyond symptom suppression. 'Chronic stress and unresolved trauma have been shown to trigger immune dysfunction, and for many women, this often goes unaddressed in traditional medical care,' says Dr. Capps. 'We need to approach autoimmune disease recovery with a full understanding of how trauma impacts the body. It's not enough to simply treat the symptoms—we need to focus on healing the underlying emotional and psychological triggers that fuel autoimmune flare-ups.' The Autoimmune Rebalance System provides participants with the tools to regulate their nervous system, heal from past trauma, and manage the chronic stress that often leads to autoimmune dysfunction. This integrated approach empowers individuals to break free from the cycle of symptom management and instead focus on lasting recovery. How the Autoimmune Rebalance System Works: A Comprehensive and Compassionate Framework The Autoimmune Rebalance System is grounded in the principles of psychoneuroimmunology, which studies the relationship between the nervous system, immune system, and endocrine system. This premium program combines cutting-edge science with compassionate behavioral health practices to rewire how women relate to their bodies, health, and healing processes. Dr. Capps has spent over a decade refining this trauma-informed approach, and it is tailored specifically to address the unique challenges women face. Medical gaslighting, emotional labor, and identity shifts are common issues for women navigating autoimmune disease, and Dr. Capps has integrated these realities into the system's design. Rather than encouraging individuals to 'push through' their symptoms, Dr. Capps' program fosters a deeper connection to the body's natural healing mechanisms, focusing on nervous system regulation, emotional resilience, and real-time integration of recovery practices into daily life. The result is a personalized approach that prioritizes sustainable healing through compassionate, non-judgmental care. A New Standard for Women's Autoimmune Recovery The Autoimmune Rebalance System stands apart by offering a level of personalization and flexibility not often found in other programs. While many traditional systems rely on rigid regimens, Dr. Capps' program emphasizes flexible frameworks and compassionate consistency. The focus is on progress and healing, not perfection. Participants are encouraged to adapt to their own unique needs and experiences—whether navigating energy shifts, managing flare-ups, or addressing emotional waves—while building sustainable recovery practices. The system does not prescribe a one-size-fits-all solution, but rather empowers women to listen to their bodies and engage in a healing process that fits their individual circumstances. This tailored approach, grounded in a deep understanding of both the clinical and emotional aspects of autoimmune disease, positions Dr. Capps' Autoimmune Rebalance System as a premier resource for women seeking to take control of their health and well-being. A Personal Journey to Empowerment and Healing Dr. Ashley Capps is not only a recognized expert in the field of autoimmune recovery but also a passionate advocate for trauma-informed care. Her personal commitment to this work is rooted in a deep understanding of the complex intersection between trauma, stress, and autoimmune disease. Having worked with hundreds of women in clinical settings, Dr. Capps has seen firsthand how untreated emotional and psychological trauma can exacerbate autoimmune conditions. Her ability to blend clinical rigor with an intuitive, compassionate approach has made her a sought-after speaker and educator in the fields of women's health, chronic illness recovery, and trauma. Her unique qualifications allow her to guide women through a healing process that combines the latest science with practical, real-life tools. As Dr. Capps continues to expand the reach of her Autoimmune Rebalance System, she remains dedicated to reshaping the conversation about autoimmune disease. She firmly believes that true healing comes from addressing both the mind and body, and this system represents her commitment to helping women reclaim their health through holistic, trauma-informed care. About Dr. Ashley Capps and the Autoimmune Rebalance System Dr. Ashley Capps is a behavioral health doctor, licensed mental health therapist, and the founder of the Autoimmune Rebalance System. She has over a decade of clinical experience in trauma recovery, psychoneuroimmunology, and integrative behavioral health. Dr. Capps' innovative program blends cutting-edge research with compassionate care to help women heal from autoimmune diseases by addressing the root causes of chronic stress and trauma. Her system has been designed to provide a holistic and sustainable recovery experience, empowering women to take control of their health through personalized, trauma-informed healing practices. Media Contact: Dr. Ashley Capps Phone: 850-527-5488 Email: [email protected] Contact Info: Name: Dr. Ashley Capps Email: Send Email Organization: The Autoimmune Rebalance System Website: Release ID: 89162375 In case of identifying any problems, concerns, or inaccuracies in the content shared in this press release, or if a press release needs to be taken down, we urge you to notify us immediately by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will be readily accessible to address your concerns and take swift action within 8 hours to rectify any issues identified or assist with the removal process. We are committed to delivering high-quality content and ensuring accuracy for our valued readers.
CNA
5 days ago
- Health
- CNA
CNA938 Rewind - A Letter to Myself: Be Kind SG's Sherry Soon overcomes her challenges to help others with theirs
CNA938 Rewind Play Sherry Soon is the founder of Be Kind SG, a charity that supports individuals with intellectual and learning challenges. When she was 19, Sherry was diagnosed with an autoimmune condition that causes intense pain in her legs and feet. But she didn't let that stop her from embarking on a journey to help others. She shares how she's managed to rally supporters to her cause and the most valuable lessons she's gained from the experience.
